Sandoz Foresees Biosimilars Unlocking Innovation
Maximizing Access Allows Healthcare Systems To Invest Savings In New Treatments
Sandoz’ global head of biopharmaceuticals says that in the context of COVID-19, biosimilars can play a key role to increase access and unlock savings that can be invested in innovation to support “the long-term sustainability of healthcare systems.”
You may also be interested in...
Medicines for Europe and IQVIA have partnered to test biosimilar sustainability in 12 European countries by issuing scorecards that measure the contribution of a country’s biosimilar policies to health systems.
Gedeon Richter has high ambitions for biosimilars, recently penning a deal to bring in a tocilizumab biosimilar that is currently under development. During its first-quarter earnings call, the Hungarian company’s CEO gave his current thinking on how payers may treat biosimilars amidst the COVID-19 pandemic.
To increase transparency and affordability, American billionaire and businessman Mark Cuban has launched a US generics venture under the name ‘the Mark Cuban Cost Plus Drugs Company.’ Cuban’s new company is hoping to introduce over 100 drugs by the end of 2021 and build a pharmaceutical factory of its own by 2022.